Niels Viggo Jensen

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet · 2017 · 175 citations · Full text

Platinum-based Therapy, Urology, Metastatic Urothelial Carcinoma +8

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason et al. · Journal of Clinical Oncology · 2021 · 122 citations · Full text

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Daniel P. Petrylak, Ronald de Wit, Kim N. et al. · The Lancet Oncology · 2019 · 83 citations · Full text

Platinum-based Therapy, Urology, Genitourinary Cancer +8

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2

Anne Vest Soerensen, Frede Donskov, Gregers G. Hermann et al. · European Journal of Cancer · 2013 · 76 citations · Full text

The influence of chemotherapy on survival after recurrence in breast cancer—a population-based study of patients treated in the 1950s, 1960s and 1970s

Søren Cold, Niels Viggo Jensen, H Brincker et al. · European Journal of Cancer · 1993 · 50 citations

Breast Oncology, Cancer Epidemiology, Medicine +7